With more than 30 years of experience in the pharmaceutical industry and a PhD in Experimental and Clinical Pharmacology, Fabienne brings extensive knowledge in quality and compliance programmes, regulatory bioanalytical strategy for biotherapeutics and vendor partnership and cross-functional interactions.
Fabienne's appointment will strengthen our SAB, who provide guidance to the company's leadership team on strategic matters, research and development initiatives, and other areas where their expertise is instrumental in advancing our bioanalytical and drug development services.
The SAB will advise the company and its leadership team on strategic matters, research and development initiatives, and other areas where their expertise is beneficial to the growth of TATAA's services.
